Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477. Epub 2015 Mar 31.


Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2.

Burckart GJ, Figg WD 2nd, Brooks MM, Green DJ, Troutman SM, Ferrell R, Chinnock R, Canter C, Addonizio L, Bernstein D, Kirklin JK, Naftel D, Price DK, Sissung TM, Girnita DM, Zeevi A, Webber SA.

J Pediatr Pharmacol Ther. 2014 Jan;19(1):16-24. doi: 10.5863/1551-6776-19.1.16.


Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.

Hall C, Troutman SM, Price DK, Figg WD, Kang MH.

Clin Genitourin Cancer. 2013 Mar;11(1):10-9. doi: 10.1016/j.clgc.2012.09.002. Epub 2012 Oct 17. Review.


Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.

Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.

Oncologist. 2012;17(3):312-20. doi: 10.1634/theoncologist.2011-0315. Epub 2012 Mar 1.


Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.

Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.

Clin Cancer Res. 2012 Apr 1;18(7):2099-107. doi: 10.1158/1078-0432.CCR-11-2484. Epub 2012 Feb 3.


Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD.

Discov Med. 2012 Jan;13(68):19-34. Review.


Prostate cancer genomic signature offers prognostic value.

Troutman SM, Price DK, Figg WD.

Cancer Biol Ther. 2010 Dec 1;10(11):1079-80. Epub 2010 Dec 1.

Supplemental Content

Loading ...
Support Center